Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study

Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study

Enrico de Nigris,1 Catrin Treharne,2 Nick Brighton,2 Ulf Holmgren,3 Andrew Walker,4 John Haughney5 1Formerly of Global Product and Portfolio Strategy, AstraZeneca, Cambridge, UK; 2Formerly of Health Economic Modelling, Regulatory and Access, Parexel International, London, UK; 3Real World Science and...

Full description

Bibliographic Details
Main Authors: de Nigris E, Treharne C, Brighton N, Holmgren U, Walker A, Haughney J
Format: Article
Language:English
Published: Dove Medical Press 2022-11-01
Series:International Journal of COPD
Subjects:
budesonide/glycopyrronium/formoterol fumarate dihydrate
chronic obstructive pulmonary disease
copd
cost-effectiveness
markov model
triple therapy
Online Access:https://www.dovepress.com/cost-effectiveness-of-triple-therapy-with-budesonideglycopyrroniumform-peer-reviewed-fulltext-article-COPD

Internet

https://www.dovepress.com/cost-effectiveness-of-triple-therapy-with-budesonideglycopyrroniumform-peer-reviewed-fulltext-article-COPD

Similar Items